E-Mail
New Orleans, LA - Research conducted by an international team of scientists discovered a mechanism that leads to Herceptin resistance, representing a significant clinical obstacle to successfully treating HER2-positive breast cancer. They also identified a new approach to potentially overcome it. The work is published online in
Nature Communications, available here. This work attempts to understand why some HER2-positive breast cancer patients do not benefit from treatment with Herceptin, which is a generally effective HER2-targeted therapy, explains Bolin Liu, MD, Professor of Genetics at LSU Health New Orleans School of Medicine and Stanley S. Scott Cancer Center.